Common questions about Ryzodeg (FAQ)
Q: How quickly does Ryzodeg start working after injection?
Ryzodeg is a combination product with a rapid-acting component, insulin aspart. According to official product information, it begins to act within 10 to 20 minutes after injection.
Q: How long does the effect of a single injection of Ryzodeg last?
The duration of effect is determined by its long-acting component, insulin degludec. Official product information states that the medicine keeps working for 24 hours or longer.
Q: Do you have to eat a meal right after taking Ryzodeg?
Ryzodeg should be administered once or twice daily along with the main meal(s). The timing of the injection is specified as being once or twice daily along with the main meal(s).
Q: What should be done if an injection site reaction occurs with Ryzodeg?
Injection site reactions, which can include pain, swelling, or redness, are common and often disappear within a few weeks of continued use. If reactions are serious or persistent, official guidance indicates that consulting a healthcare provider is appropriate, as a change in treatment may be required.
Q: Can Ryzodeg cause low blood sugar (hypoglycemia)?
Yes, like all insulin products, Ryzodeg can cause low blood sugar, which is also called hypoglycemia. This is the most frequent adverse reaction and is classified as Very Common in regulatory documents. Official patient information notes the signs of low blood sugar.
Q: Does Ryzodeg interact with blood pressure medications?
Official regulatory documents identify certain categories of medicines that can affect how Ryzodeg works. Specific types of blood pressure medications, such as beta-blockers and ACE inhibitors, may intensify the medicine's glucose-lowering effect, and co-administration may result in closer monitoring of glucose levels.
Q: Is it safe to drink alcohol while using Ryzodeg?
Alcohol consumption is a documented interaction that can either increase or decrease the glucose-lowering effect of insulin. Regulatory information states that alcohol consumption may increase the risk of low blood sugar, and that limiting intake or avoiding drinking on an empty stomach is advised.
Q: Are there any foods or drinks that should be avoided because of Ryzodeg?
No specific foods are listed as being restricted by the medicine, but alcohol consumption is a known interaction. Any significant change in diet may alter insulin needs and should be discussed with a healthcare provider.
Q: What does the research say about Ryzodeg and cardiovascular outcomes?
Regulatory reviews of the clinical trial data have examined the potential for cardiovascular risk. These reviews concluded that the data did not show an excess in major adverse cardiovascular events (MACE) compared to other approved long-acting insulin products.
Q: Are there official studies comparing the frequency of low blood sugar events with Ryzodeg?
Yes, clinical trials were conducted to compare Ryzodeg against other established insulin regimens. These studies monitored the rates of hypoglycemia (low blood sugar), and some research noted differences in the frequency of nocturnal low blood sugar when compared to certain established insulin combinations.
Q: Has Ryzodeg been studied in elderly patients?
Yes, regulatory documents indicate that the medicine's safety and response patterns have been observed in older adults (age 65 and older). These studies primarily focused on how the medicine is processed by the body, known as pharmacokinetic research.
Q: What is the official safety classification for Ryzodeg?
The safety profile is similar to other insulin products, with the primary risk being low blood sugar (hypoglycemia). Special monitoring or management is described as necessary for young pediatric patients and patients with renal (kidney) or hepatic (liver) impairment.
Q: Can Ryzodeg be used alongside non-insulin diabetes pills?
Yes, Ryzodeg may be used with some oral antidiabetic medicines, but co-administration with other medicines is determined based on individual patient circumstances. Official safety information specifies risks for certain combinations, such as the potential for fluid retention when used with thiazolidinediones (TZDs).
Q: What are the contraindications listed for Ryzodeg?
Ryzodeg is contraindicated if a patient has a known allergy or hypersensitivity to the active substances (insulin degludec or insulin aspart) or any of the inactive ingredients. It is also contraindicated if the patient is currently experiencing an episode of hypoglycemia.
Q: Is Ryzodeg the same as Tresiba, or is it different?
No, they are different medicines. Ryzodeg is a fixed-ratio combination of two active insulins: insulin degludec (long-acting) and insulin aspart (rapid-acting). Tresiba is a single-component product that contains only insulin degludec.
Q: What should I know about switching from another insulin to Ryzodeg?
Official protocols state that switching between different insulin regimens should be completed under medical supervision. This typically involves close blood glucose monitoring and individualized dose adjustments during and in the weeks following the transition to Ryzodeg.
Q: What non-prescription or herbal supplements might interact with Ryzodeg?
The use of certain vitamins, herbal supplements, and other non-prescription medicines may affect blood sugar control. Regulatory guidance emphasizes that patients should inform their healthcare provider about all products used.
Q: Can Ryzodeg affect vision?
Changes in vision are often listed as symptoms of both very high and very low blood sugar levels. Additionally, official documents state that a rapid improvement in blood sugar control when starting insulin can cause a temporary worsening of an existing condition called diabetic retinopathy.
Q: Is it normal to feel a stinging or burning sensation when injecting Ryzodeg?
Injection site reactions, including pain, swelling, or redness, are listed as common adverse reactions. If serious or continuing reactions occur, consulting a healthcare provider is noted as appropriate.
Q: What is the chemical name for the insulins found in Ryzodeg?
The active substances in the medicine are referred to by their non-proprietary names in official documents: insulin degludec (the long-acting component) and insulin aspart (the rapid-acting component).
Q: What are the official recommendations for monitoring while taking Ryzodeg?
Official monitoring recommendations include blood glucose monitoring, blood ketone, and Glycated Hemoglobin ( HbA1c) levels as clinically indicated. Intensified monitoring is described as necessary in certain patient populations.
Q: Does Ryzodeg have a long shelf life?
Official storage instructions define the in-use period for the medicine. Once the injection pen is opened and in use, it should be stored at room temperature and must be discarded after 28 days, even if there is still medicine remaining.
Q: Are there any restrictions on physical activity while using Ryzodeg?
No restrictions on physical activity are listed in regulatory documents. However, unplanned strenuous exercise may increase the risk of low blood sugar (hypoglycemia), and dose adjustments may be appropriate if a change occurs in the usual level of physical activity.
Q: What should a patient do if they accidentally inject too much Ryzodeg?
Accidental injection of too much Ryzodeg can lead to hypoglycemia (low blood sugar). Management focuses on treating low blood sugar by immediately consuming a quick source of sugar and seeking medical assistance for severe cases where consciousness is lost.
Q: Is it possible to be allergic to an ingredient in Ryzodeg?
Yes, official safety information indicates that Ryzodeg is contraindicated if a patient has an allergy or hypersensitivity to the active substances (insulin degludec or insulin aspart) or any of the inactive ingredients (excipients) in the pen.
Q: Does Ryzodeg require a prescription from a healthcare professional?
Official documents describe Ryzodeg as a prescription-only medication, indicating its use should be under the supervision of a licensed healthcare provider.
